Development and external validation of a machine learning model for cardiovascular risk prediction in individuals with chronic lung disease: Evidence from CHARLS and ELSA - Top-Institutions - MDSpire

Development and external validation of a machine learning model for cardiovascular risk prediction in individuals with chronic lung disease: Evidence from CHARLS and ELSA

  • By

  • Ankang Zhu

  • Shuai Wei

  • Haobo Wang

  • Shaodong Liu

  • Yang Li

  • Xiaojie Pan

  • Xingcai Gao

  • Xing Lin

  • June 8, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    China Health and Retirement Longitudinal Study (CHARLS)
    China Health and Retirement Longitudinal Study (CHARLS)

    Beijing, Beijing

    Key Differentiators

    • Cardiology
    • Public Health

  • #2

    English Longitudinal Study of Ageing (ELSA)
    English Longitudinal Study of Ageing (ELSA)

    London, England

    Key Differentiators

    • Cardiology
    • Geriatrics

  • #3

    North Estonia Medical Centre (NEMC) Foundation
    North Estonia Medical Centre (NEMC) Foundation

    Tallinn, Harju County

    Key Differentiators

    • Cardiology
    • Oncology

  • #4

    Stanford NSCLC Radiogenomics
    Stanford NSCLC Radiogenomics

    Stanford, California

    Key Differentiators

    • Cardiology
    • Radiology

Original Source(s)

Development and external validation of a machine learning model for cardiovascular risk prediction in individuals with chronic lung disease: Evidence from CHARLS and ELSA

  • by Ankang Zhu, Shuai Wei, Haobo Wang, Shaodong Liu, Yang Li, Xiaojie Pan, Xingcai Gao, Xing Lin

  • June 8, 2026

Related Content

Specialty Areas in Respiratory Care that Offer a Slower Pace

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.

First-line serplulimab plus chemotherapy versus chemotherapy alone in small-cell lung cancer patients with brain metastases: a multicenter, prospective cohort study